28 related articles for article (PubMed ID: 38554320)
1. Prognostic value of CD146 in solid tumor: A Systematic Review and Meta-analysis.
Zeng P; Li H; Lu PH; Zhou LN; Tang M; Liu CY; Chen MB
Sci Rep; 2017 Jun; 7(1):4223. PubMed ID: 28652617
[TBL] [Abstract][Full Text] [Related]
2. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines.
Zabouo G; Imbert AM; Jacquemier J; Finetti P; Moreau T; Esterni B; Birnbaum D; Bertucci F; Chabannon C
Breast Cancer Res; 2009; 11(1):R1. PubMed ID: 19123925
[TBL] [Abstract][Full Text] [Related]
3. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer.
Zeng Q; Li W; Lu D; Wu Z; Duan H; Luo Y; Feng J; Yang D; Fu L; Yan X
Proc Natl Acad Sci U S A; 2012 Jan; 109(4):1127-32. PubMed ID: 22210108
[TBL] [Abstract][Full Text] [Related]
4. Nestin and cluster of differentiation 146 expression in breast cancer: Predicting early recurrence by targeting metastasis?
Tampaki EC; Tampakis A; Nonni A; Kontzoglou K; Patsouris E; Kouraklis G
Tumour Biol; 2017 Mar; 39(3):1010428317691181. PubMed ID: 28347241
[TBL] [Abstract][Full Text] [Related]
5. ImmunoPET of CD146 in Orthotopic and Metastatic Breast Cancer Models.
Li C; Kang L; Fan K; Ferreira CA; Becker KV; Huo N; Liu H; Yang Y; Engle JW; Wang R; Xu X; Jiang D; Cai W
Bioconjug Chem; 2021 Jul; 32(7):1306-1314. PubMed ID: 33475350
[TBL] [Abstract][Full Text] [Related]
6. CD146 as a prognostic marker in breast cancer: A meta-analysis.
Sharma A; Somasundaram I; Chabaud MB
J Cancer Res Ther; 2024 Jan; 20(1):193-198. PubMed ID: 38554320
[TBL] [Abstract][Full Text] [Related]
7. CD146, from a melanoma cell adhesion molecule to a signaling receptor.
Wang Z; Xu Q; Zhang N; Du X; Xu G; Yan X
Signal Transduct Target Ther; 2020 Aug; 5(1):148. PubMed ID: 32782280
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and clinicopathological value of Slug protein expression in breast cancer: a systematic review and meta-analysis.
Zhang Z; Fang T; Lv Y
World J Surg Oncol; 2022 Nov; 20(1):361. PubMed ID: 36372891
[TBL] [Abstract][Full Text] [Related]
9. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis.
Ji Y; Wang H
World J Surg Oncol; 2020 Aug; 18(1):197. PubMed ID: 32767977
[TBL] [Abstract][Full Text] [Related]
10. Platinum-containing regimens for metastatic breast cancer.
Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.
Ibrahim EM; Al-Foheidi ME; Al-Mansour MM; Kazkaz GA
Breast Cancer Res Treat; 2014 Dec; 148(3):467-76. PubMed ID: 25361613
[TBL] [Abstract][Full Text] [Related]
12. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
